What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Amgen's unaudited financial results for the third quarter and the first nine months of 2007. It also details the company's use of non-GAAP financial measures and the specific adjustments made to GAAP figures.

What are the main reasons Amgen is presenting non-GAAP financial results?

Amgen is presenting non-GAAP financial results to provide investors with what it believes is a clearer view of its underlying operational performance. These measures exclude significant, often non-recurring or non-cash items such as restructuring charges, acquisition-related costs, and the impact of expensing stock options, allowing for better period-over-period comparisons.

What are the significant 'Restructuring Charges' mentioned in the filing?

The restructuring charges relate to a plan announced in August 2007 to rationalize Amgen's worldwide manufacturing and research facilities. These charges include severance costs, asset impairment, accelerated depreciation for a production facility, and lease-related losses for R&D facilities that will no longer be used.

How do recent acquisitions impact the reported financial results?

Several recent and past acquisitions, including Alantos, Ilypsa, Avidia, Abgenix, Tularik, and Immunex, have led to various expenses and adjustments. These include the amortization of acquired intangible assets, charges related to in-process R&D, merger integration costs, and inventory adjustments due to changes in accounting for acquired assets.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 24, 2007, to report its unaudited financial results for the third quarter and first nine months of 2007. The filing primarily focuses on the company's presentation of non-GAAP financial measures, which exclude various charges and expenses to provide what Amgen believes is a more useful view of its operational performance for investors. Key adjustments include costs related to stock option expensing (SFAS No. 123R), significant restructuring charges stemming from a plan announced in August 2007 involving manufacturing and research facility rationalization, charges from recent acquisitions (Alantos, Ilypsa, Avidia, Abgenix, Tularik, Immunex), inventory write-offs, manufacturing asset write-offs, and certain tax benefits. The company emphasizes that these non-GAAP measures are supplementary and not a replacement for GAAP reporting, offering insights into performance before, during, and after these significant events.

Key Highlights

1Amgen reported its unaudited financial results for the three and nine months ended September 30, 2007.
2The company provided non-GAAP financial measures, excluding items like stock option expensing, restructuring charges, and acquisition-related expenses.
3Significant restructuring charges are detailed, including severance, asset impairments, accelerated depreciation, and lease-related losses, driven by manufacturing and research facility rationalization.
4The results reflect adjustments for various acquisitions, including Alantos, Ilypsa, Avidia, Abgenix, Tularik, and Immunex.
5Other adjustments to non-GAAP measures include inventory write-offs, manufacturing asset write-offs, and a tax benefit related to transfer pricing resolution.
6Amgen believes these non-GAAP measures offer useful supplementary information for investors to analyze performance.
7The filing also includes comparative non-GAAP data for the same periods in 2006, adjusting for stock option expensing and prior acquisition-related charges.

AMGEN INC 8-K Report, Financial Results (Oct 24, 2007)

Summary

Key Highlights

Frequently Asked Questions